rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

BioVie Inc.

BIVI · Nasdaq

Health CareBiotechnologyNot moving yet

BIVI stood above a rising 150-day average in 10 of the last 51 weekly readings, and has been out of that trend for the last 4 weeks. It is 18.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$98K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
34 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 51 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$95KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Joanne Wendy KimChief Financial Officerbought2,500at $2.1828 Aug 2026filed 28 Aug 2026
Amy Suzon ChappellDirectorbought727at $2.1628 Aug 2026filed 28 Aug 2026
Joseph M. PalumboChief Medical Officerbought4,843at $2.1628 Aug 2026filed 28 Aug 2026
Cuong V. DoPresident & CEObought15,210at $2.0827 Aug 2026filed 28 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders34+6 on the quarter
New · exited7 · 2
Reported value$2.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MORGAN STANLEYadded · filed 13 Aug 2026605,471$1.2M+530,250+704.9%
Diametric Capital, LPreduced · filed 14 Aug 2026256,636$498K-113,364−30.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026127,918$248K+60,000+88.3%
CITADEL ADVISORS LLCadded · filed 14 Aug 202695,952$186K+50,660+111.9%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202670,906$138K-13,161−15.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202670,752$137K-13,451−16.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202637,557$73K00.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 202635,860$70K+13,069+57.3%
PRELUDE CAPITAL MANAGEMENT, LLCreduced · filed 14 Aug 202632,583$63K-59,480−64.6%
NORTHERN TRUST CORPadded · filed 13 Aug 202621,820$42K+7,631+53.8%
30 Sep 2024 – 30 Jun 2026
283542Sep 24Mar 25Sep 25Dec 25Jun 26

News

BioVie reports positive Phase 2 Parkinson's data for bezisterimproactiveinvestors.com · 20 Oct 2026BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meetingmanilatimes.net · 20 Oct 2026BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroupsproactiveinvestors.com · 19 Oct 2026BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom Burdenrttnews.com · 19 Oct 2026BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meetingmanilatimes.net · 19 Oct 2026BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meetingproactiveinvestors.com · 14 Oct 2026New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Globalcaliforniatelegraph.com · 26 Sep 2026New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Globaltennesseedaily.com · 19 Sep 2026

Everyone who traded it

Amy Suzon Chappell Company insiderDirector · last 28 Aug 20261 · 0
Joanne Wendy Kim Company insiderChief Financial Officer · last 28 Aug 20262 · 0
Joseph M. Palumbo Company insiderChief Medical Officer · last 28 Aug 20261 · 0
Cuong Do V Company insiderPresident & CEO · last 27 Aug 20264 · 0
James Paul Lang Company insiderDirector · last 5 Jan 20260 · 0
Kameel D. Farag Company insiderDirector · last 5 Jan 20260 · 0
Michael Edward Sherman Company insiderDirector · last 5 Jan 20260 · 0
Sigmund Rogich Company insiderDirector · last 5 Jan 20260 · 0
Richard J. Berman Company insiderDirector · last 20 Dec 20240 · 5
Robert J. Hariri Company insiderDirector · last 20 Dec 20240 · 0
Steve Gorlin Company insiderDirector · last 1 Dec 20237 · 2
Christopher Reading Company insiderEVP Neuroscience R&D · last 16 Feb 20230 · 0

Same industry

IOVA Iovance BiotherapeuticsLeading+124%
MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
ABCL AbCellera BiologicsLeading+50%
HALO Halozyme TherapeuticsLeading+47%
XNCR XencorLeading+44%
XERS Xeris Biopharma HoldingsLeading+42%
CPIX Cumberland PharmaceuticalsLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2026 · to 10 Aug 20260.0%
Cash and equivalentsFY 2026 · to 30 Jun 2026$9.0M

Analyst forecasts

No analyst forecasts yet.